Literature DB >> 11988336

Effect of repeated administration of morphine on the activity of extracellular signal regulated kinase in the mouse brain.

Minoru Narita1, Masumi Ioka, Masami Suzuki, Michiko Narita, Tsutomu Suzuki.   

Abstract

The present study was designed to determine whether chronic morphine treatment could influence the activity of extracellular signal regulated kinase (ERK) in the mouse brain. The single subcutaneous injection of morphine produced profound antinociception and an increase in phosphorylated-ERK (p-ERK) immunoreactivity in the pons/medulla, and these effects were blocked by a mu-opioid receptor antagonist, naloxone. The potency of antinociception induced by the second morphine injection at 24 h after the first morphine injection was similar to that by the first morphine injection. The p-ERK immunoreactivity in the pons/medulla obtained at 24 h after a single injection of morphine was not different from the control level. Repeated morphine injection once a day for 7 days resulted in a marked reduction of antinociception by morphine. The p-ERK immunoreactivity in the pons/medulla increased remarkably after 7 days repeated morphine injection. These data suggest that the sustained activation of ERK activity be associated with the development of antinociceptive tolerance to morphine in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988336     DOI: 10.1016/s0304-3940(02)00141-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence.

Authors:  Yong Chen; Claudia Sommer
Journal:  Mol Neurobiol       Date:  2009-05-26       Impact factor: 5.590

2.  Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat.

Authors:  Tara A Macey; Erin N Bobeck; Deborah M Hegarty; Sue A Aicher; Susan L Ingram; Michael M Morgan
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

3.  Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons.

Authors:  Tara A Macey; Janet D Lowe; Charles Chavkin
Journal:  J Biol Chem       Date:  2006-09-18       Impact factor: 5.157

Review 4.  Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human.

Authors:  Michael M Morgan; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 5.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

6.  Opiate-induced hypernociception and chemokine receptors.

Authors:  Fletcher White; Natalie Wilson
Journal:  Neuropharmacology       Date:  2009-07-15       Impact factor: 5.250

7.  Down-regulation of c-Cbl by morphine accounts for persistent ERK1/2 signaling in delta-opioid receptor-expressing HEK293 cells.

Authors:  Daniela A Eisinger; Hermann Ammer
Journal:  J Biol Chem       Date:  2009-10-14       Impact factor: 5.157

8.  Change in functional selectivity of morphine with the development of antinociceptive tolerance.

Authors:  T A Macey; E N Bobeck; K L Suchland; M M Morgan; S L Ingram
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 9.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

10.  Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?

Authors:  Elisa Mura; Stefano Govoni; Marco Racchi; Valeria Carossa; Guglielmina Nadia Ranzani; Massimo Allegri; Ron Hn van Schaik
Journal:  J Pain Res       Date:  2013-05-01       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.